Choroidal Neovascularization

• 

  Subject Areas on Research

  • A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. 
  • A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection. 
  • A prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy. 
  • Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. 
  • Adenoma of the retinal pigment epithelium simulating a juxtapapillary choroidal neovascular membrane. 
  • Age as an independent risk factor for severity of experimental choroidal neovascularization. 
  • Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration: Systematic Literature Review and Expert Opinion. 
  • Appearance of pediatric choroidal neovascular membranes on optical coherence tomography angiography. 
  • Aryl hydrocarbon receptor knock-out exacerbates choroidal neovascularization via multiple pathogenic pathways. 
  • Association of Pediatric Choroidal Neovascular Membranes at the Temporal Edge of Optic Nerve and Retinochoroidal Coloboma. 
  • Association of genetic variants on 8p21 and 4q12 with age-related macular degeneration in Asian populations. 
  • Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study. 
  • Blood-derived macrophages infiltrate the retina and activate Muller glial cells under experimental choroidal neovascularization. 
  • Bone marrow transplantation transfers age-related susceptibility to neovascular remodeling in murine laser-induced choroidal neovascularization. 
  • Bone marrow-derived progenitor cells contribute to experimental choroidal neovascularization. 
  • Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. 
  • Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration. 
  • Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial. 
  • Choriovitreal Neovascularization After Resolution of Infectious Chorioretinitis. 
  • Choroidal Neovascularization in Familial Transthyretin Amyloidosis. 
  • Choroidal Remodeling in Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-month Prospective Study. 
  • Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study. 
  • Choroidal neovascularization in a child with infantile primary hyperoxaluria treated with bevacizumab. 
  • Choroidal neovascularization in pathological myopia. 
  • Choroidal thickness and risk characteristics of eyes with myopic choroidal neovascularization. 
  • Clinicopathologic studies of eyes that were obtained postmortem from four patients who were enrolled in the submacular surgery trials: SST Report No. 16. 
  • Comparison of 2D reconstructions of surgically excised subfoveal choroidal neovascularization with fluorescein angiographic features: SST report No. 15. 
  • Complement-mediated release of fibroblast growth factor 2 from human RPE cells. 
  • Correlation of pathologic features in spectral domain optical coherence tomography with conventional retinal studies. 
  • Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients With Polypoidal Choroidal Vasculopathy. 
  • Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis). 
  • Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. 
  • Description of the Age-Related Eye Disease Study 9-step severity scale applied to participants in the Complications of Age-related Macular Degeneration Prevention Trial. 
  • Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Diagnostic and therapeutic challenges. 
  • Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid. 
  • Dynamic indocyanine green angiography-guided focal thermal laser treatment of fibrotic choroidal neovascularization. 
  • Effect of Anti-C5a Therapy in a Murine Model of Early/Intermediate Dry Age-Related Macular Degeneration. 
  • Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. 
  • Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. 
  • Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19. 
  • Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration. 
  • Functional changes after photodynamic therapy with verteporfin. 
  • Gender and estrogen supplementation increases severity of experimental choroidal neovascularization. 
  • HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. 
  • HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. 
  • Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. 
  • Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: submacular surgery trials report no. 7. 
  • IMPROVED SPECIFICITY OF POLYPOIDAL CHOROIDAL VASCULOPATHY DIAGNOSIS USING A MODIFIED EVEREST CRITERIA. 
  • Impact of fluorescein angiographic characteristics of macular lesions on outcomes after macular translocation 360 degree surgery in eyes with age-related macular degeneration. 
  • Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial. 
  • Incidence of Fellow Eye Involvement in Patients With Unilateral Exudative Age-Related Macular Degeneration. 
  • Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. 
  • Independent effects of complement factor H Y402H polymorphism and cigarette smoking on risk of age-related macular degeneration. 
  • Induced corneal astigmatism after macular translocation surgery with scleral infolding. 
  • Insulin-like growth factor-1 contributes to neovascularization in age-related macular degeneration. 
  • Interferon gamma-inducible protein-10 (IP-10) and eotaxin as biomarkers in age-related macular degeneration. 
  • Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. 
  • Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration. 
  • Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. 
  • Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. 
  • Late outgrowth endothelial progenitor cells in patients with age-related macular degeneration. 
  • Macrophage activation associated with chronic murine cytomegalovirus infection results in more severe experimental choroidal neovascularization. 
  • Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. 
  • Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. 
  • Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Macular translocation surgery with 360-degree peripheral retinectomy following ocular photodynamic therapy of choroidal neovascularization. 
  • Macular translocation with 360-degree peripheral retinectomy impact of technique and surgical experience on visual outcomes. 
  • Macular translocation with radial scleral ouffolding: experimental studies and initial human results. 
  • Management of eyes with both idiopathic macular hole and choroidal neovascularization. 
  • Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization? 
  • Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials. 
  • Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. 
  • Myopic choroidal neovascularisation: current concepts and update on clinical management. 
  • Neovascular age-related macular degeneration and its association with LOC387715 and complement factor H polymorphism. 
  • Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. 
  • Nicotine increases size and severity of experimental choroidal neovascularization. 
  • Night vision symptoms and progression of age-related macular degeneration in the Complications of Age-related Macular Degeneration Prevention Trial. 
  • OCT Risk Factors for Development of Late Age-Related Macular Degeneration in the Fellow Eyes of Patients Enrolled in the HARBOR Study. 
  • Optical Coherence Tomography Reflective Drusen Substructures Predict Progression to Geographic Atrophy in Age-related Macular Degeneration. 
  • Optical coherence tomography following photodynamic therapy with verteporfin for subfoveal predominantly classic choroidal neovascularization. 
  • Optical coherence tomography reader agreement in neovascular age-related macular degeneration. 
  • Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). 
  • Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). 
  • Photodynamic therapy and intravitreal triamcinolone for extrafoveal choroidal neovascularization in neovascular age-related macular degeneration. 
  • Photodynamic therapy for predominantly hemorrhagic lesions in neovascular age-related macular degeneration. 
  • Photoreceptor synapses degenerate early in experimental choroidal neovascularization. 
  • Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and Management. 
  • Polypoidal choroidal vasculopathy and systemic lupus erythematosus. 
  • Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Prevalence and Risk Factors for Nonexudative Neovascularization in Fellow Eyes of Patients With Unilateral Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. 
  • Preventing stem cell incorporation into choroidal neovascularization by targeting homing and attachment factors. 
  • Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration. 
  • Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization. 
  • RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. 
  • Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results. 
  • Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. 
  • Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. 
  • Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE. 
  • Rare Complication of Sclerochoroidal Calcifications. 
  • Recovery of the neurosensory retina after macular translocation surgery is independent of preoperative macular sensitivity in neovascular age-related macular degeneration. 
  • Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. 
  • Recurrence of retinal pigment epithelial changes after macular translocation with 360 degrees peripheral retinectomy for geographic atrophy. 
  • Recurrent choroidal neovascularization after macular translocation surgery with 360-degree peripheral retinectomy. 
  • Relationship of smoking and cardiovascular risk factors with polypoidal choroidal vasculopathy and age-related macular degeneration in Chinese persons. 
  • Reply. 
  • Resolution of persistent pigment epithelial detachment secondary to polypoidal choroidal vasculopathy in response to Aflibercept. 
  • Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization--SST Report No. 1. 
  • Retinal pigment epithelial tear with vitreomacular attachment: a novel pathogenic feature. 
  • Retrospective review of eyes with neovascular age-related macular degeneration treated with photodynamic therapy with verteporfin and intravitreal triamcinolone. 
  • Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. 
  • Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. 
  • Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes submacular surgery trials pilot study report number 1. 
  • Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: II. Quality of life outcomes submacular surgery trials pilot study report number 2. 
  • Successful macular translocation with temporary scleral infolding using absorbable sture. 
  • Suppression of aberrant choroidal neovascularization through activation of the aryl hydrocarbon receptor. 
  • Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9. 
  • Systemic, Ocular and Genetic Risk Factors for Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Singaporeans. 
  • THREE-YEAR RESULTS OF POLYPOIDAL CHOROIDAL VASCULOPATHY TREATED WITH PHOTODYNAMIC THERAPY: Retrospective Study and Systematic Review. 
  • The ARMS2 A69S variant and bilateral advanced age-related macular degeneration. 
  • The association of prior cytomegalovirus infection with neovascular age-related macular degeneration. 
  • The fibroblast growth factor receptors, FGFR-1 and FGFR-2, mediate two independent signalling pathways in human retinal pigment epithelial cells. 
  • The impact of typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy on vision-related quality of life in Asian patients. 
  • The incidence of neovascular membranes and visual field defects from optic nerve head drusen in children. 
  • The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. 
  • The natural history of polypoidal choroidal vasculopathy: a multi-center series of untreated Asian patients. 
  • Toll-like receptor 3 polymorphism rs3775291 is not associated with choroidal neovascularization or polypoidal choroidal vasculopathy in Chinese subjects. 
  • Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial. 
  • Treatment of age-related macular degeneration. 
  • Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. 
  • Understanding indocyanine green angiography in polypoidal choroidal vasculopathy: the group experience with digital fundus photography and confocal scanning laser ophthalmoscopy. 
  • Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19. 
  • β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. 
• 

  Keywords of People

  • Bowes Rickman, Catherine, George and Geneva Boguslavsky Distinguished Professor of Eye Research, Cell Biology
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Toth, Cynthia Ann, Joseph A.C. Wadsworth Distinguished Professor of Ophthalmology, Biomedical Engineering